

Special Issue

Advances in Plasma Cell Dyscrasias

Message from the Guest Editors

Plasma cell dyscrasias are a biologically and clinically heterogeneous group of diseases primarily characterized by the clonal expansion of plasma cells and monoclonal protein secretion. Significant research advances in the field during the past few years have led to improved outcomes for patients with multiple myeloma, AL amyloidosis and lymphoproliferative disorders. The ever-increasing understanding of the molecular mechanisms involved in disease pathogenesis and interactions in the tumor microenvironment have led to improved diagnostics, prognostication and novel agent development. Minimal residual disease assessment by NGF and NGS is being increasingly incorporated into clinical practice.

Immunotherapy will probably be the next revolution in treatment for plasma cell malignancies. Patients with plasma cell leukemia, POEMs and other rare entities have also benefited from the development of new agents. The goal of this Special Issue is to highlight important advances that have taken place in the diagnosis, management and treatment of plasma cell dyscrasias in recent years, and welcomes all papers that address aspects in these areas.

Guest Editors

Dr. Despina Fotiou

Dr. Maria Gavriatopoulou

Dr. Ioannis Ntanasis-Stathopoulos

Deadline for manuscript submissions

closed (15 August 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/143620

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)